Premium
The paclitaxel‐eluting Coroflex™ please stent pilot study (PECOPS I): Acute and 6‐month clinical and angiographic follow‐up
Author(s) -
Unverdorben Martin,
Degenhardt Ralf,
Vallbracht Christian,
Wiemer Marcus,
Horstkotte Dieter,
Schneider Henrik,
Nienaber Christoph,
Bocksch Wolfgang,
Gross Michael,
Boxberger Michael
Publication year - 2006
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.20731
Subject(s) - medicine , restenosis , stent , lesion , stenosis , target lesion , myocardial infarction , radiology , mace , angioplasty , surgery , cardiology , percutaneous coronary intervention
Background and Objectives : Various active stent coatings significantly reduce restenosis rates and target lesion revascularization compared to bare metal stents. Therefore, the procedural and 6‐month performance of the new paclitaxel‐eluting Coroflex™. Please stent was investigated. Methods : Ninety‐seven patients (66 ± 7.6 years, 34/97(35.1%) diabetics, 11/97(11.3%) unstable angina) were enrolled per protocol for elective single stent deployment into native coronary de‐novo or post‐PTCA restenotic lesions (stenosis: ≥ 70%, < 100%; reference diameter ≥ 2.25 mm and <3.3 mm; lesion length ≤ 16 mm) with 13/97(13.4%) lesion type A, 64/97(66%) type B1, 20/97(20.6%) type B2). The mean reference diameter was 2.88 ± 0.42 mm, the lesion length 10.03 ± 2.93 mm, and the minimal lumen diameter 0.64 ± 0.22 mm. Results : The success rates of procedure and study stent deployment were 100% and 94.8%, respectively. In 5/97(5.2%) two stents were implanted. Follow‐up was performed clinically in 86/87(98.9%) and angiographically in 77/87(88.5%) patients after 6.1 ± 0.7 months. Major adverse cardiac events occurred in 7/87(8%) 1/87(1.2%) subacute thrombosis 10.3hrs post procedure, 1/87(1.2%) myocardial infarction, 5/87(5.7%) target lesion revascularizations. The in‐segment stenosis declined from 78 ± 7.2% to 9.4 ± 6.2% after stenting increasing to 31.9 ± 18.6% at follow‐up. The in‐segment late loss and the late loss index were 0.47 ± 0.6 mm and 0.23 ± 0.29 resulting in 6/77(7.8%) in‐segment restenoses three each of which were located either within or beyond the stent structure. The outcome was neither influenced by the prevalence of diabetes ( p = 0.4), hypercholesterolemia ( p = 1), hypertension ( p = 1), overweight ( p = 1), nor by the family history of coronary artery disease ( p = 0.7). Conclusion : The data of the paclitaxel‐eluting Coroflex™. Please stent tested in PECOPS I are within the range other available paclitaxel‐eluting stent. © 2006 Wiley‐Liss, Inc.